Advanced in Malignant Mixed Mullerian Tumor

Dr. Sandeep K. Jain

Oncology
Novacare Outpatient Rehabilitation East, Inc.
480 Hwy 96 E, 
Vadnais Heights, MN 
Accepting New Patients
Advanced in Malignant Mixed Mullerian Tumor
Novacare Outpatient Rehabilitation East, Inc.
480 Hwy 96 E, 
Vadnais Heights, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sandeep Jain is an Oncologist in Vadnais Heights, Minnesota. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Lung Cancer, Small Cell Lung Cancer (SCLC), Pacemaker Implantation, and Cataract Removal. Dr. Jain is currently accepting new patients.

His clinical research consists of co-authoring 271 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
St Francis Regional Medical Center
M Health Fairview Southdale Hospital
Abbott Northwestern Hospital
M Health Fairview Ridges Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PreferredOne
  • HMO
  • OTHER COMMERCIAL
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

NOVACARE OUTPATIENT REHABILITATION EAST, INC.
480 Hwy 96 E, Vadnais Heights, MN 55127

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug, Device
Study Phase: Not Applicable
Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)
Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Other
Aveir Dual-Chamber Leadless i2i IDE Study
Aveir Dual-Chamber Leadless i2i IDE Study
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Device
Study Phase: Not Applicable
Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Device
Study Phase: Not Applicable
ArcticLine Feasibility Study
ArcticLine Feasibility Study
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Device
Study Phase: Not Applicable
Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST)
Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST)
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer
Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2024
Intervention Type: Drug
Study Drug: Nimotuzumab
Study Phase: Phase 3
Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)
Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)
Enrollment Status: Completed
Publish Date: January 03, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Recombinant Human Deoxyribonuclease (rhDNase) Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Recombinant Human Deoxyribonuclease (rhDNase) Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
Enrollment Status: Terminated
Publish Date: September 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Randomized, Placebo-controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Intravenous Immunoglobulin (IVIG) Eye Drops in Patients With Dry Eye Disease
A Phase I/II Randomized, Placebo-controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Intravenous Immunoglobulin (IVIG) Eye Drops in Patients With Dry Eye Disease
Enrollment Status: Completed
Publish Date: April 10, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease
Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease
Enrollment Status: Terminated
Publish Date: January 18, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Enrollment Status: Terminated
Publish Date: November 08, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India
A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India
Enrollment Status: Completed
Publish Date: May 15, 2018
Intervention Type: Drug
View 12 Less Clinical Trials

270 Total Publications

Delayed Migration of a Valve-in-Valve Transcatheter Aortic Valve Implantation.
Delayed Migration of a Valve-in-Valve Transcatheter Aortic Valve Implantation.
Journal: CASE (Philadelphia, Pa.)
Published: July 30, 2025
Similar Doctors
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Ann C. Casey
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Ann C. Casey
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
6025 Lake Road, Ste 110, 
Woodbury, MN 
 (12.1 miles away)
651-735-7414
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ann Casey is a Gynecologic Oncologist and an Oncologist in Woodbury, Minnesota. Dr. Casey is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, Hernia Surgery, and Hysterectomy. Dr. Casey is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Jessica A. Thomes-Pepin
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Jessica A. Thomes-Pepin
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Minnesota Oncology Hematology PA

6025 Lake Rd, Suite 110, 
Woodbury, MN 
 (12.1 miles away)
651-735-7414
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jessica Thomes-Pepin is a Gynecologic Oncologist and an Oncologist in Woodbury, Minnesota. Dr. Thomes-Pepin has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Sertoli-Leydig Cell Tumor, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, and Bladder Reconstruction. Dr. Thomes-Pepin is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Angela J. Ziebarth
Gynecologic Oncology | Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Angela J. Ziebarth
Gynecologic Oncology | Oncology

Minnesota Oncology Hematology PA

6025 Lake Rd, Suite 110, 
Woodbury, MN 
 (12.1 miles away)
651-735-7414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angela Ziebarth is a Gynecologic Oncologist and an Oncologist in Woodbury, Minnesota. Dr. Ziebarth is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Ovarian Cancer, Ovarian Cysts, Vaginal Cancer, Oophorectomy, and Lymphadenectomy. Dr. Ziebarth is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 46 Advanced Conditions
    View All 112 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile